<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "https://jats.nlm.nih.gov/archiving/1.3/JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">journal-of-respiratory-medicine-and-research</journal-id>
      <journal-title-group>
        <journal-title>Journal of Respiratory Medicine and Research</journal-title>
      </journal-title-group>
      <issn publication-format="electronic">2831-3240</issn>
      <publisher>
        <publisher-name>Directive Publications</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.52338/jrmr.2025.5218</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Early Detection Of Renal Injury In Elderly Patients With Chronic Obstructive Pulmonary Disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Morsi</surname>
            <given-names>Shimaa Nour</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tawfeek</surname>
            <given-names>Ahmed</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Noureldin</surname>
            <given-names>Ahmed Nagah</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dongol</surname>
            <given-names>Eptehal M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gadallah</surname>
            <given-names>Doaa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Chest diseases, Faculty of Medicine, Sohag University, Egypt</aff>
        <aff id="aff2"><label>2</label>Department of Clinical and chemical pathology, Faculty of Medicine, Sohag University, Egypt</aff>
        <aff id="aff3"><label>3</label>Department of internal medicine, Faculty of Medicine, Sohag University, Egypt</aff>
        <aff id="aff4"><label>4</label>Department of Chest diseases, Qena Faculty of Medicine, South Valley University, Egypt</aff>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-21">
        <day>21</day>
        <month>11</month>
        <year>2025</year>
      </pub-date>
      <volume>14</volume>
      <issue>1</issue>
      <history>
        <date date-type="received" iso-8601-date="2025-10-29">
          <day>29</day>
          <month>10</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2025 The Author(s). Published by Directive Publications.</copyright-statement>
        <copyright-year>2025</copyright-year>
        <copyright-holder>The Author(s)</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an open access article distributed under the terms of the CC BY 4.0 licence (https://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <self-uri content-type="html" xlink:href="https://directivepublications.org/journal-of-respiratory-medicine-and-research/early-detection-of-renal-injury-in-elderly-patients-with-chronic-obstructive-pulmonary-disease"/>
      <self-uri content-type="pdf" xlink:href="https://directivepublications.org/pdf/606/early-detection-of-renal-injury-in-elderly-patients-with-chronic-obstructive-pulmonary-disease.pdf"/>
      <abstract>
        <p>Background: One prevalent complication of COPD is renal damage. Our objective is to examine the function of cystatin C and β2 microglobulin as indicators for detecting early kidney damage among older individuals with stable COPD and during exacerbations. Methods: Prospective comparative cross-sectional study recruited 135 COPD cases, classified as 86 COPD cases with acute exacerbation (AECOPD) admitted to the respiratory department in Sohag University Hospital and 49 patients with stable COPD during the period from September 2023 to March 2024. Serum level of creatinine, cystatin C and B2 microglobulin were measured on admission. Results: The mean age of the 85 male cases was 68.2 i 4.51 years. Compared to stable COPD, AECOPD cases had considerably higher mean serum levels of β2 microglobulin and cystatin C (P value = 0.001 for both). A significant positive correlation was identified between β2 micro- globulin and cystatin C (r= 0.539 and P value &lt;  0.001) and PaCO2 (r= 0.137 and P value &lt;  0.001) while a significant negative correlation with PaO2 (r= -0.785 and P value &lt;  0.001) in AECOPD. As regard cystatin C, there was significant positive correlation with β2 micro-globulin (r= 0.539 and P value &lt;  0.001) and PaCO2 (r= 0.003 and P value &lt;  0.001) while a significant negative correlation with PaO2 (r= -0.161and P-value = 0.045) in AECOPD. Conclusion: Elderly individuals with AECOPD frequently experience acute kidney injury, which is positively correlated with the severity of hypoxemia and hypercapnia. Cys-C and β2-MG can be used as sensitive indicators to detect renal impairment early in older adults with AECOPD.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Acute Kidney Injury</kwd>
        <kwd>B2 microglobulin and biomarkers</kwd>
        <kwd>COPD</kwd>
        <kwd>Cystatin C</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement>Non</funding-statement>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec id="background">
      <label>1</label>
      <title>Background</title>
      <p>Chronic Obstructive Pulmonary Disease (COPD) Is Marked By Persistent Airway Inflammation, Systemic Effects Or Comorbidities, And Poor Reversibility Of Airflow Obstruction<sup>[<xref ref-type="bibr" rid="ref-1">1</xref>–<xref ref-type="bibr" rid="ref-3">3</xref>]</sup></p>
      <p>With 3.5 Million Fatalities From COPD In 2021—Nearly 5% Of All Deaths—It Ranks As The Fourth Most Common Cause Of Mortality Worldwide.<sup>[<xref ref-type="bibr" rid="ref-4">4</xref>]</sup></p>
      <p>Numerous Comorbid Diseases, Such As Diabetes Mellitus (DM), Heart Failure (HF), Ischemic Heart Disease, And Chronic Kidney Disease (CKD), Prevail In The Cases With COPD And Are Associated With Greater Mortality Rates And Morbidity Costs. <sup>[<xref ref-type="bibr" rid="ref-5">5</xref>]</sup></p>
      <p>Numerous Investigations Have Suggested A Possible Connection Between Renal Insufficiency And COPD<sup>[<xref ref-type="bibr" rid="ref-6">6</xref>]</sup> Furthermore, Hypoxemia, Carbon Dioxide Retention, Prolonged Ischemia, And Inflammation Can All Contribute To Or Exacerbate Kidney Injury During A COPD Exacerbation. Acute Kidney Injury (AKI) Is Therefore Rather Common In Cases Who Are Hospitalized As A Result Of Exacerbations Of COPD. Thus, It Is Essential To Detect And Treat Renal Damage In COPD Patients As Soon As Possible.<sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup></p>
      <p>Deterioration In Health Status Is A Result Of COPD Exacerbation (AECOPD), One Of The Main Causes Of Disease And Death.<sup>[<xref ref-type="bibr" rid="ref-8">8</xref>, <xref ref-type="bibr" rid="ref-9">9</xref>]</sup></p>
      <p>Significant Gas Trapping, Higher Mucus Formation, And Intensified Airway Inflammation Are Generally Associated With AECOPD. The Main Manifestation Of An Exacerbation Is Worsening Of Dyspnea, Which Is Caused By These Changes. Other Symptoms Include Increased Coughing And Wheezing, As Well As An Increase In The Amount And Purulence Of Sputum. <sup>[<xref ref-type="bibr" rid="ref-10">10</xref>]</sup></p>
      <p>Although Serum Creatinine (Scr) Is Frequently Utilized For The Detection And Evaluation Of Kidney Impairment, There Are Usually No Appreciable Changes In Scr In Early Phases Of Injuries In The Kidney. An Increase In Scr Levels Frequently Indicates That The Kidneys Have Already Sustained An Irreparable And Quickly Developing Injury. Scr Levels Is Impacted By A Wide Range Of Parameters, Such As Age, Sex, Food, Muscle Mass, Drugs, And Other Factors. <sup>[<xref ref-type="bibr" rid="ref-11">11</xref>]</sup> More Rapid And Sensitive Biological Markers Are Therefore Required.</p>
      <p>One Well-Known Member Of The Cystatin Superfamily, Notably Family Ii, Is Serum Cystatin C (Cys-C). It Is Widely Dispersed In Different Body Fluids And Is Uninterruptedly Secreted By Nucleated Cells Throughout The Body. It Works As A Soluble, Non-Glycosylated Inhibitor Of Cysteine Proteases. Numerous External Stimuli Have Little Effect On Its Steady-State Secretion And Excretion. The Renal Proximal Tubules, Which Do Not Secrete Cys-C Themselves, Completely Reabsorb And Metabolize Cys-C, Which Can Easily Cross The Glomerular Filtration Membrane. It Is A Great Biomarker For Determining The Glomerular Filtration Rate (GFR) Because Of This Feature. <sup>[<xref ref-type="bibr" rid="ref-12">12</xref>]</sup> According To Earlier Research, Serum Cys-C Levels May Provide A More Reliable Indicator Of GFR Than Creatinine Levels Since They Are Only Influenced By GFR. <sup>[<xref ref-type="bibr" rid="ref-13">13</xref>–<xref ref-type="bibr" rid="ref-15">15</xref>]</sup></p>
      <p>A Low-Molecular-Weight Protein, Beta-2 (Β2) Microglobulin (Β2-Mg) Is Easily Filtered Throug The Glomerular Membrane And Then Processed In The Renal Tubules. <sup>[<xref ref-type="bibr" rid="ref-16">16</xref>]</sup> It Is Produced, Synthesized, And Released At A Steady Rate In A Healthy Population.About 99 Percent Of Β2-Mg Is Reabsorbed And Metabolized In The Proximal Tubule After Passing Through The Glomerulus. This Biomarker Has Been Used To Track Glomerular Activity As Well As To Assess Tubular Function. According To Earlier Research, Β2-Mg Might Be A More Accurate Indicator Of Acute Renal Damage Than Serum Creatinine (Scr) .<sup>[<xref ref-type="bibr" rid="ref-17">17</xref>]</sup></p>
      <p>Investigating The Function Of Cys-C And Β2-Mg As Indicators For Detection Of Early Kidney Injury In Older Individuals With Stable COPD And During Exacerbations Is The Goal Of Our Study.</p>
    </sec>
    <sec id="materials-and-methods">
      <label>2</label>
      <title>Materials and Methods</title>
      <sec id="study-design-and-setting">
        <label>2.1</label>
        <title>Study Design And Setting</title>
        <p>In The Present Prospective Comparative-Cross-Sectional Study, 49 Patients With Stable COPD Were Recruited From An Outpatient Clinic Between September 2023 And March 2024, While 86 Cases With Acute Exacerbations Were Admitted To The Respiratory Department At Sohag University Hospital.</p>
        <p>In Line With The 2024 Gold (Global Initiative For Chronic Obstructive Lung Disease), COPD Exacerbation Features Dyspnea And/Or Cough And Sputum That Worsen Over &lt;14 Days. <sup>[<xref ref-type="bibr" rid="ref-18">18</xref>]</sup></p>
        <p>Patients With COPD Who Are Not Currently Having An Exacerbation Of Their Condition Are Said To Have Stable COPD. These Individuals May, However, Have Persistent COPD Symptoms Of Variable Severity Or Have Recently Undergone Exacerbations Followed By Recovery To A New Baseline. <sup>[<xref ref-type="bibr" rid="ref-19">19</xref>]</sup></p>
        <p>Based On The Oxygen Partial Pressure (PaO2) Readings From The Arterial Blood Gas Study Performed At Admission, Three Groups Of Cases Were Formed: Group A Had PaO2 Levels Above 60 mmHg But Below 80 Mm Hg, Which Indicated Mild Hypoxemia; Group B Had PaO2 Levels Above 40 mmHg And Up To 60 mmHg, Which Indicated Moderate Hypoxemia; And Group C Had PaO2 Levels At Or Below 40 mmHg, Which Indicated Severe Hypoxemia. <sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup></p>
      </sec>
      <sec id="ethics-approval-and-consent-to-participate">
        <label>2.2</label>
        <title>Ethics Approval And Consent To Participate</title>
        <p>The Present Study Received Approval From The Sohag Faculty Of Medicine’s Medical Research Ethics Committee. The Institutional Review Board Registration Number Of The Study Was Soh-Med-23-06-04pd.</p>
      </sec>
      <sec id="inclusion-and-exclusion-criteria">
        <label>2.3</label>
        <title>Inclusion And Exclusion Criteria</title>
        <p>All Patients With A Clinically Confirmed Diagnosis Of COPD, Post-Bronchodilator Spirometry, FEV1/FVC &lt; 70%, And Who Were Admitted To Our Department Throughout The Study Period Were Included In The Trial, As Were Cases Over 65 And Those Who Signed An Informed Consent Form.</p>
        <p>Patients With Cardiovascular Diseases, Multiple Organ Failures, Primary Or Secondary Renal Diseases, Cancer, Hematological Disorders, Cerebrovascular Diseases (CVD), Patients Who Had Received Nephrotoxic Medications Within Six Weeks Prior To Admission, Patients Who Refused To Participate In The Study, And Patients Who Showed Clinical And/Or Radiographic Signs Of Other Pulmonary Conditions Other Than COPD Were All Excluded.</p>
      </sec>
      <sec id="data-collection-method">
        <label>2.4</label>
        <title>Data Collection Method</title>
        <p>Every Patient Underwent The Following: Taking A History, Which Included Respiratory Symptoms Like Coughing, Dyspnoea, Etc.; Recording Other Information, Including Blood Pressure, Sex, Age, Body Mass Index (BMI), Smoking Index, Number Of Exacerbations Per Year, And Severity Of Exacerbation; And Performing A Clinical Examination And Radiological Evaluation, Which Included Chest Radiography, Echocardiography, High Resolution Computed Tomography Scanning Of The Chest, And Abdominal Ultrasound To Examine The Urinary System, Including Kidneys, Ureters, And Bladder. The Measurements Of The Serum Level Of Creatinine, Cystatin C And B2 Microglobulin Were Carried Out On Admission.</p>
      </sec>
      <sec id="method-of-measurement-of-serum-creatinine">
        <label>2.5</label>
        <title>Method Of Measurement Of Serum Creatinine</title>
        <p>Creatinine In Serum Or Urine Is Measured By The Jaffe’s Reaction, Which Uses Creatinine And Picric Acid To Quantitatively Produce An Orange Color In An Alkaline Medium. After The Passage Of 15 Minutes At Room Temperature, Incubation For Color Development, The Color Was Measured At 520 Nm<sup>[<xref ref-type="bibr" rid="ref-20">20</xref>]</sup>. Adult Males Typically Have 0.6–1.2 mg/dl Of Creatinine, While Adult Females Typically Have 0.5–1.1 Mg/Dl.</p>
      </sec>
      <sec id="method-of-measurement-of-serum-cystatin-c">
        <label>2.6</label>
        <title>Method Of Measurement Of Serum Cystatin C</title>
        <p>As Directed By The Manufacturer, Serum Cystatin C Was Measured Using A Particle-Enhanced Immuneturbidimetric Test On A Cobas 6000 Analyzer (Roche Diagnostics, Indianapolis, In, Usa). The Assay Is A Two-Reagent System That Has An Eight-Week Stability Period. Reagents 1 And 2 Are A Buffer And A Suspension Of Latex Particles Coated With Polyclonal Antibodies Specific To Rabbit Anti-Cystatin C, Respectively. This Method Involves Mixing The Sample With Reagent 1 In A Cuvette Rotor, Then Adding Reagent 2. The Usual Amount Of Cystatin C (Male: 0.71-1.21 Mg/L, Female: 0.61-1.05 Mg/L) <sup>[<xref ref-type="bibr" rid="ref-21">21</xref>]</sup> Is Tested 10 Minutes After The Agglutination Reaction Begins (546 Nm For Primary Wavelength And 700 Nm For Secondary Wavelength). <sup>[<xref ref-type="bibr" rid="ref-22">22</xref>]</sup></p>
      </sec>
      <sec id="method-of-measurement-of-serum-b2-microglobulin">
        <label>2.7</label>
        <title>Method Of Measurement Of Serum B2 Microglobulin</title>
        <p>Following The Recommendations Of The Company <bold><sup>[<xref ref-type="bibr" rid="ref-22">22</xref>]</sup></bold>, The Measurement Of The Serum B2 Microglobulin Was Carried Out Using An Immunoturbidimetric Assay On A Cobas 6000 Analyzer (Roche Diagnostics, Indianapolis, In, Usa). The Normal Range For B2 Microglobulin Is Between 07 And 2.1 Mg/L. <bold><sup>[<xref ref-type="bibr" rid="ref-22">22</xref>]</sup></bold></p>
      </sec>
      <sec id="statistical-analysis">
        <label>2.8</label>
        <title>Statistical Analysis</title>
        <p>The Data Were Collected And Tabulated. Data Were Statistically Analysed Using The Spss Package V. 27. Testing Normality Using The Shapiro-Wilk Test Revealed That The Quantitative Variables Are Not Normally Distributed (P-Value Of Normality Test Was Less Than 0.005), So Non-Parametric Analysis Was Done. The Quantitative Variables Were Expressed In Terms Of Mean±Standard Deviation, Whereas The Categorical Variables Were Given In Frequency And Percent. In Addition, The Mann–Whitney Test Was Utilized To Make Comparisons Between Two Groups, And Kruskal–Wallis Non-Parametric Tests Were Used For Comparison Of Three Or More Groups Because The Data Was Not Normally Distributed. To Assess The Correlation Between The Β2 Micro-Globulin, Cystatin C And Other Possible Factors, Spearman’s Rho Was Used.</p>
        <p>Linear Regression Model Was Done To Investigate The Different Predictors For Acute Renal Injury. We Started With Univariate Linear Regression For Both The Level Of Β2 Micro Globulin And Cystatin C Separately For All Variables Included In The Study And The Variables With Significance Were Included In The Multivariate Linear Regression Analysis Was Done To See The Possible Predictors In The Whole Study.</p>
      </sec>
    </sec>
    <sec id="results">
      <label>3</label>
      <title>Results</title>
      <p>135 Patients With Copd Were Included In The Study; 85 Of Them Were Men, And Their Mean Age Was 68.2±4.51 Years. Cases Were Classified Into Two Categories: Those With Stable COPD (49, Or 36.3% Of The Total) And Those With Acute Exacerbation Of COPD (86, Or 63.7%).</p>
      <p>The Groups Under Study Were Compared In <bold><xref ref-type="table" rid="table-1">Table 1</xref>.</bold> Regarding Demographic Data, Gender And Body Mass Index Did Not Significantly Differ Between The Groups Under Study, But The Groups Had A Difference With Statistical Significance In Age Between The Groups; AECOPD Cases Were Older Than Stable Copd Cases (P Value 0.01). In Terms Of Arterial Blood Gas, The AECOPD Cases Had Statistically Significant Lower PaO2 (58.1<sup>i</sup> 16.2) And Higher PaC02 (58.1<sup>i</sup> 18) Values Than Those With Stable COPD (P Value = 0.001 For Both). The Mean Blood Levels Of Β2 Microglobulin And Cystatin C Were Substantially Greater In AECOPD Patients Than In Stable COPD Patients (P Value = 0.001 For Both). However, There Were No Statistically Significant Differences In The Levels Of Serum Creatine Between Both Groups. Compared To Stable COPD Cases, AECOPD Cases Had Significantly Higher Systolic And Diastolic Blood Pressure Levels (P Value = 0.001 For Both).</p>
      <p>Aecopd Patients With Normal Oxygen Tension (16 Cases) And Those With Hypoxemia (70 Cases) Were Compared In Table (2). The Authors Noticed No Significant Differences Concerning Bmi, Sex, Age, Or Serum Creatinine Level, But They Differed Significantly In Terms Of Acute Kidney Injury Markers (Β2 Microglobulin And Cystatin C) (2.01±0.451 Vs 2.89±0.73, 1.33±0.184 Vs 1.46±0.21, Respectively), With A P Value Less Than 0.05.</p>
      <table-wrap id="table-1">
        <label>Table 1</label>
        <caption>
          <p>Comparison between the stable COPD and COPD AE patients:</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"/>
              <th scope="col"><bold>All COPD</bold></th>
              <th scope="col"><bold>Stable COPD (n=49)</bold></th>
              <th scope="col"><bold>COPD AE (n=86)</bold></th>
              <th scope="col"><bold>P-value</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row"><bold>Age (years)</bold></th>
              <td>68.2±4.51</td>
              <td>64.7±3.19</td>
              <td>70.2±3.91</td>
              <td>0.01</td>
            </tr>
            <tr>
              <th scope="row"><bold>Gender (no%) Female Male</bold></th>
              <td>50(37) 85(63)</td>
              <td>22(44.9) 27(55.1)</td>
              <td>28(32.6) 58(67.4)</td>
              <td>0.15</td>
            </tr>
            <tr>
              <th scope="row"><bold>BMI (kg/m<sup>2</sup> )</bold></th>
              <td>24.8±4.97</td>
              <td>23.2±1.38</td>
              <td>25.7±5.95</td>
              <td>0.18</td>
            </tr>
            <tr>
              <th scope="row"><bold>PO2 (mmHg)</bold></th>
              <td>69.9±20.4</td>
              <td>90.8±2.06</td>
              <td>58.1±16.2</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>PCO2 (mmHg)</bold></th>
              <td>50.4±16.8</td>
              <td>38.2±2.93</td>
              <td>58.1±18</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Creatinine</bold></th>
              <td>0.799±0.218</td>
              <td>0.808±0.233</td>
              <td>0.794±0.211</td>
              <td>0.77</td>
            </tr>
            <tr>
              <th scope="row"><bold>β2 micro globulin</bold></th>
              <td>2.17±0.981</td>
              <td>1.18±0.303</td>
              <td>2.73±0.768</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Cystatin C</bold></th>
              <td>1.25±0.319</td>
              <td>0.914±0.165</td>
              <td>1.44±0.21</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Systolic bl. pressure</bold></th>
              <td>124±17.1</td>
              <td>114±9.53</td>
              <td>129±17.9</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Diastolic bl. pressure</bold></th>
              <td>78.9±10.2</td>
              <td>73.7±8.83</td>
              <td>81.9±9.76</td>
              <td><bold>0.001</bold></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The Mann-Whitney U test was used.</p>
      <p>The Comparison Of The Hypoxemia Subgroups Is Displayed In The Remaining Section Of <bold>Table (2)</bold>. The Cases Were Distributed To The Following Groups: Although The Mean Level Of Β2 Microglobulin And Cystatin C Is Higher With The Severity Of Hypoxaemia, The Authors Observed The Lack Of Any Significant Differences Between The Levels Of These Two Markers And Different Grades Of Hypoxemia For PaO2 Tension Of 60-80 mmHg (Mild Hypoxemia), 40-60 mmHg (Moderate Hypoxemia), And Less Than 40 mmHg (Severe Hypoxemia), Which Included 10 Cases.</p>
      <table-wrap id="table-2">
        <label>Table 2</label>
        <caption>
          <p>Comparison among different grades of hypoxaemia in COPD patients with acute exacerbation:</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"/>
              <th scope="col"><bold>COPD AE With Normoxemia (n=16)</bold></th>
              <th scope="col"><bold>COPD AE with Hypoxaemia (n=70)</bold></th>
              <th scope="col"><bold>P-value*</bold></th>
              <th scope="col"><bold>Mild hypoxaemia (PaO2 60-80 mmHg) (n=16)</bold></th>
              <th scope="col"><bold>Moderate hypoxaemia (PaO2 40-60 mmHg) (n=44)</bold></th>
              <th scope="col"><bold>Severe hypoxaemia (PaO2 &lt;40 mmHg) (n=10)</bold></th>
              <th scope="col"><bold>P-value+</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row"><bold>Age (years)</bold></th>
              <td>69.3±1.53</td>
              <td>70.5±4.25</td>
              <td>0.505</td>
              <td>69.6±4.59</td>
              <td>70.5±4.3</td>
              <td>71.8±3.42</td>
              <td>0.382</td>
            </tr>
            <tr>
              <th scope="row"><bold>Gender (no%) Female Male</bold></th>
              <td>8(50) 8(50)</td>
              <td>20(28.6) 50(71.4)</td>
              <td>0.105</td>
              <td>6(37.5) 10(62.5)</td>
              <td>10(22.7) 34(77.3)</td>
              <td>4(40) 6(60)</td>
              <td>0.367</td>
            </tr>
            <tr>
              <th scope="row"><bold>BMI (kg/m2)</bold></th>
              <td>29.6±8.78</td>
              <td>24.9±4.75</td>
              <td>0.16</td>
              <td>26.7±4.76</td>
              <td>24.1±4.49</td>
              <td>25.32±5.44</td>
              <td>0.183</td>
            </tr>
            <tr>
              <th scope="row"><bold>PaO2 mmHg</bold></th>
              <td>83.9±3.76</td>
              <td>52.2±11.5</td>
              <td><bold>0.001</bold></td>
              <td>67.9±6.5</td>
              <td>50.31±5.52</td>
              <td>35.2±4.49</td>
              <td><bold>0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>PaCO2 mmHg</bold></th>
              <td>42.8±4.75</td>
              <td>60.6±17.7</td>
              <td><bold>0.001</bold></td>
              <td>53.1±12.02</td>
              <td>61.54±19.1</td>
              <td>68.8±15.5</td>
              <td><bold>0.028</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>S. Creat.</bold></th>
              <td>0.762±0.205</td>
              <td>0.801±0.213</td>
              <td>0.625</td>
              <td>0.825±0.3</td>
              <td>0.757±0.13</td>
              <td>0.96±0.28</td>
              <td>0.079</td>
            </tr>
            <tr>
              <th scope="row"><bold>β2 micrglobulin.</bold></th>
              <td>2.01±0.451</td>
              <td>2.89±0.73</td>
              <td><bold>0.001</bold></td>
              <td>2.69±0.905</td>
              <td>2.94±0.68</td>
              <td>2.99±0.63</td>
              <td>0.465</td>
            </tr>
            <tr>
              <th scope="row"><bold>Cystatin C</bold></th>
              <td>1.33±0.184</td>
              <td>1.46±0.21</td>
              <td><bold>0.005</bold></td>
              <td>1.45±0.33</td>
              <td>1.46±0.14</td>
              <td>1.49±0.22</td>
              <td>0.261</td>
            </tr>
            <tr>
              <th scope="row"><bold>Systolic bl. Pressure</bold></th>
              <td>128±8.56</td>
              <td>130±19.5</td>
              <td>0.89</td>
              <td>133±12.4</td>
              <td>128±21.8</td>
              <td>134±18.4</td>
              <td>0.198</td>
            </tr>
            <tr>
              <th scope="row"><bold>Diastolic bl. Pressure</bold></th>
              <td>85±5.16</td>
              <td>81.1±10.4</td>
              <td>0.096</td>
              <td>85±11.5</td>
              <td>79.5±9.87</td>
              <td>82±10.3</td>
              <td>0.277</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>* Mann-Whitney U test +Kruskal-Wallis non-parametric among hypoxemic groups</p>
      <p>The Relationship Between Various Factors And B2 Micro Globulin Is Displayed In <bold>Table (3)</bold>. In Patients Experiencing An Acute Exacerbation, A Significantly Negative Correlation Was Found Between Β2 Microglobulin And Partial Arterial Tension Of Oxygen (PaO2) (R=-0.785 And P Value &lt; 0.001), While There Was A Significant Positive Correlation Between Β2 Microglobulin And Cystatin C (R= 0.539 And P-Value &lt; 0.001) And PaCO@ (R= 0.137 And P-Value &lt; 0.001).</p>
      <table-wrap id="table-3">
        <label>Table 3</label>
        <caption>
          <p>Correlation between different parameters and Β2 micro globulin:</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"/>
              <th scope="col" colspan="2"><bold>Stable COPD (49 pt.)</bold></th>
              <th scope="col" colspan="2"><bold>A.E. COPD with normal PaO2 (16 pt)</bold></th>
              <th scope="col" colspan="2"><bold>A.E. COPD with hypoxaemia (70 pt)</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row"/>
              <td><bold>Spearman rho (r)</bold></td>
              <td><bold>P-value</bold></td>
              <td><bold>Spearman rho (r)</bold></td>
              <td><bold>P-value</bold></td>
              <td><bold>Spearman rho (r)</bold></td>
              <td><bold>P-value</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Cystatin C</bold></th>
              <td>0.013</td>
              <td>0.928</td>
              <td>0.687</td>
              <td><bold>0.003</bold></td>
              <td>0.539</td>
              <td><bold>&lt; 0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Serum creatinine</bold></th>
              <td>0.103</td>
              <td>0.48</td>
              <td>0.21</td>
              <td>0.435</td>
              <td>0.064</td>
              <td>0.6</td>
            </tr>
            <tr>
              <th scope="row"><bold>PaO2</bold></th>
              <td>-0.246</td>
              <td>0.088</td>
              <td>-0.785</td>
              <td><bold>&lt; 0.001</bold></td>
              <td>-0.268</td>
              <td><bold>0.025</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>PaCO2</bold></th>
              <td>0.458</td>
              <td>0.001</td>
              <td>0.785</td>
              <td><bold>0.259</bold></td>
              <td>0.137</td>
              <td><bold>&lt;0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Systolic BP</bold></th>
              <td>0.136</td>
              <td>0.35</td>
              <td>0.466</td>
              <td>0.069</td>
              <td>0.063</td>
              <td>0.606</td>
            </tr>
            <tr>
              <th scope="row"><bold>Diastolic BP</bold></th>
              <td>0.06</td>
              <td>0.63</td>
              <td>0.22</td>
              <td>0.414</td>
              <td>0.008</td>
              <td>0.949</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Spearman’s rho was used.</p>
      <p>In A Similar Analysis, We Found That In Patients Experiencing Acute Exacerbation, There Was A Significant Negative Correlation With Partial Arterial O2 Tension (PaO2) (R=-0.161 And P-Value = 0.045) And A Significant Positive Correlation With Β2 Micro-Globulin (R= 0.539 And P-Value &lt; 0.001) And PaCO2 (R= 0.003 And P-Value &lt; 0.001) <bold>(<xref ref-type="table" rid="table-4">Table 4</xref>)</bold>.</p>
      <table-wrap id="table-4">
        <label>Table 4</label>
        <caption>
          <p>Correlation between different parameters and Cystatin C:</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/606-43f53768b8e7b74c1736/tbl-68.png" mimetype="image" mime-subtype="png"/>
        <table-wrap-foot>
          <p>Shown as printed in the PDF. View in PDF (page 5)</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Spearman’s rho was used.</p>
      <p>The Multivariate Linear Regression Analysis Model To Look Into Potential Factors For The Level Of Β2 Microglobulin Was Displayed In <bold><xref ref-type="table" rid="table-5">Table 5</xref></bold>.Significant Predictors Of The Rise In Β2 Microglobulin Levels Included Age, Cystatin C, PaO2 Tension, And The Degree Of Hypoxemia.The Amount Of Β2 Micro-Globulin Increased By 0.015 For Every Unit Drop In Oxygen Tension.</p>
      <table-wrap id="table-5">
        <label>Table 5</label>
        <caption>
          <p>Multivariate logistic Linear regression analysis of possible predictors for the level of β2 micro-globulin:</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"/>
              <th scope="col" colspan="2"><bold>Univariate linear regression</bold></th>
              <th scope="col" colspan="4"><bold>Multivariate linear regression</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row"/>
              <td rowspan="2"><bold>Coefficient (B)</bold></td>
              <td rowspan="2"><bold>P value</bold></td>
              <td rowspan="2"><bold>Coefficient (B)</bold></td>
              <td colspan="2"><bold>95%CI</bold></td>
              <td rowspan="2"><bold>P value</bold></td>
            </tr>
            <tr>
              <th scope="row"/>
              <td><bold>Upper</bold></td>
              <td><bold>Lower</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Age</bold></th>
              <td>0.0903</td>
              <td><bold>0.001</bold></td>
              <td>-0.027</td>
              <td>-0.052</td>
              <td>-0.003</td>
              <td><bold>0.025</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Cystatin C</bold></th>
              <td>2.48</td>
              <td><bold>0.0001</bold></td>
              <td>1.479</td>
              <td>1.007</td>
              <td>1.951</td>
              <td><bold>&lt; 0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>PO2</bold></th>
              <td>-0.036</td>
              <td><bold>0.001</bold></td>
              <td>-0.015</td>
              <td>-0.026</td>
              <td>-0.003</td>
              <td>0.011</td>
            </tr>
            <tr>
              <th scope="row"><bold>PaCO2</bold></th>
              <td>0.0271</td>
              <td><bold>0.0001</bold></td>
              <td>-0.006</td>
              <td>-0.014</td>
              <td>9.72</td>
              <td>0.086</td>
            </tr>
            <tr>
              <th scope="row"><bold>Systolic BP</bold></th>
              <td>0.021</td>
              <td><bold>0.001</bold></td>
              <td>-2.39</td>
              <td>-0.007</td>
              <td>0.0069</td>
              <td>0.948</td>
            </tr>
            <tr>
              <th scope="row"><bold>Diastolic BP</bold></th>
              <td>0.026</td>
              <td><bold>0.0001</bold></td>
              <td>0.006</td>
              <td>-0.005</td>
              <td>0.0184</td>
              <td>0.297</td>
            </tr>
            <tr>
              <th scope="row"><bold>Having AECOPD</bold></th>
              <td>1.54</td>
              <td><bold>0.001</bold></td>
              <td>0.188</td>
              <td>-0.57</td>
              <td>0.2018</td>
              <td>0.341</td>
            </tr>
            <tr>
              <th scope="row"><bold>Severity of hypoxaemia</bold></th>
              <td>1.5</td>
              <td><bold>0.001</bold></td>
              <td>0.403</td>
              <td>-0.83</td>
              <td>0.0259</td>
              <td><bold>0.045</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Sex ‘female’</bold></th>
              <td>0.45</td>
              <td><bold>0.015</bold></td>
              <td>-0.066</td>
              <td>-0.2615</td>
              <td>0.128</td>
              <td>0.503</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The Multivariate Linear Regression Analysis Model Employed In Order To Look Into Potential Factors For The Amount Of Cystatin C Was Displayed In <bold><xref ref-type="table" rid="table-6">Table 6</xref></bold>.The Presence Of AECOPD, Female Patients, And Β2 Microglobulin Were Significant Predictors Of Increased Cystatin C Levels, Although The Presence And Severity Of Hypoxemia Were Not.</p>
      <table-wrap id="table-6">
        <label>Table 6</label>
        <caption>
          <p>Multivariate logistic Linear regression analysis of possible predictors for the level of Cystatin C.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"/>
              <th scope="col" colspan="2"><bold>Univariate linear regression</bold></th>
              <th scope="col" colspan="4"><bold>Multivariate linear regression</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row"/>
              <td rowspan="2"><bold>Coefficient (B)</bold></td>
              <td rowspan="2"><bold>P value</bold></td>
              <td rowspan="2"><bold>Coefficient (B)</bold></td>
              <td colspan="2"><bold>95%CI</bold></td>
              <td rowspan="2"><bold>P value</bold></td>
            </tr>
            <tr>
              <th scope="row"/>
              <td><bold>Upper</bold></td>
              <td><bold>Lower</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Age</bold></th>
              <td>0.034</td>
              <td><bold>0.0001</bold></td>
              <td>0.0058</td>
              <td>-0.002</td>
              <td>0.014</td>
              <td>0.157</td>
            </tr>
            <tr>
              <th scope="row"><bold>β2 micro-globulin</bold></th>
              <td>0.263</td>
              <td><bold>0.001</bold></td>
              <td>0.159</td>
              <td>0.108</td>
              <td>0.21</td>
              <td><bold>&lt; 0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>PO2</bold></th>
              <td>-0.016</td>
              <td><bold>0.001</bold></td>
              <td>0.00173</td>
              <td>-0.0021</td>
              <td>0.005</td>
              <td>0.378</td>
            </tr>
            <tr>
              <th scope="row"><bold>PaCO2</bold></th>
              <td>0.007</td>
              <td><bold>0.001</bold></td>
              <td>-5.704</td>
              <td>-0.0031</td>
              <td>0.002</td>
              <td>0.661</td>
            </tr>
            <tr>
              <th scope="row"><bold>Systolic BP</bold></th>
              <td>0.005</td>
              <td><bold>0.001</bold></td>
              <td>7.705</td>
              <td>-0.002</td>
              <td>0.0024</td>
              <td>0.948</td>
            </tr>
            <tr>
              <th scope="row"><bold>Diastolic BP</bold></th>
              <td>0.007</td>
              <td><bold>0.004</bold></td>
              <td>-0.0026</td>
              <td>-0.006</td>
              <td>0.0012</td>
              <td>0.181</td>
            </tr>
            <tr>
              <th scope="row"><bold>Having AECOPD</bold></th>
              <td>0.525</td>
              <td><bold>0.001</bold></td>
              <td>-0.31104</td>
              <td>-0.426</td>
              <td>-0.195</td>
              <td><bold>&lt; 0.001</bold></td>
            </tr>
            <tr>
              <th scope="row"><bold>Severity of Hypoxaemia</bold></th>
              <td>0.445</td>
              <td><bold>0.001</bold></td>
              <td>-0.01662</td>
              <td>-0.159</td>
              <td>0.125</td>
              <td>0.818</td>
            </tr>
            <tr>
              <th scope="row"><bold>Sex: Female</bold></th>
              <td>0.17</td>
              <td><bold>0.002</bold></td>
              <td>0.088</td>
              <td>0.026</td>
              <td>0.151</td>
              <td><bold>0.006</bold></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="discussion">
      <label>4</label>
      <title>Discussion</title>
      <p>COPD Has Negative Clinical Consequences For Numerous Organs. Aecopd Patients Often Suffer From Acute Kidney Injury (AKI), Which Is Associated With Worse Prognosis And Higher Use Of Medical Resources. <sup>[<xref ref-type="bibr" rid="ref-25">25</xref>]</sup></p>
      <p>In Patients Experiencing AECOPD, AKI Is Shown To Be An Independent Risk Factor For In-Hospital Death. <sup>[<xref ref-type="bibr" rid="ref-26">26</xref>]</sup> According To A Study By Barakat Mf et al., The Prevalent Level Of AKI Among Cases Experiencing Aecopd Amounted To 1.9%, Whereas The Incidence Of AKI In People Experiencing Chronic Obstructive Lung Disease (COPD) Was 128 Instances Per 100,000 Person-Years. <sup>[<xref ref-type="bibr" rid="ref-27">27</xref>]</sup> Additionally, Compared To Patients Without AKI, People Experiencing AECOPD With AKI Showed A 1.80-Fold Higher Chance Of Dying Within The First Six Months After A COPD Exacerbation. <sup>[<xref ref-type="bibr" rid="ref-27">27</xref>]</sup></p>
      <p>Serum Creatinine (Scr) And Blood Urea Nitrogen (BUN) Values Are Known To Vary Only When Renal Function Has Already Been Severely Damaged, Making Them Unreliable Indicators Of Renal Impairment, Especially In Its Early Stages. <sup>[<xref ref-type="bibr" rid="ref-11">11</xref>]</sup> . On The Other Hand, Beta-2-Microglobulin (Β2-Mg) And Cystatin C (Cys-C) Are Both Tiny Molecules Whose Levels Inside The Body Don’t Change In Response To Environmental Influences. The Renal Tubular Epithelium Is Where These Compounds Are Mainly Reabsorbed Before Being Broken Down And Eliminated Through Urine.</p>
      <p>When Renal Tubular Injury Occurs, The Reabsorption Of Both Cystatin C (Cys-C) And Beta-2-Microglobulin (Β2-Mg) Decreases, Resulting In Increased Serum Levels <sup>[<xref ref-type="bibr" rid="ref-28">28</xref>]</sup> . In Order To Detect Acute Renal Injury Among Cases With Chronic Obstructive Pulmonary Disease (COPD), We Investigated The Possibility Of Using Cys-C And Β2-Mg As Biological Markers.</p>
      <p>Serum Creatinine Levels In This Study Were Found To Be Within The Normal Range, And There Were No Discernible Differences Between The Stable COPD And AECOPD Groups. This Finding Matches The Findings Of A Study Conducted By Chen D et al., Which Found That Serum Creatinine (Scr) In Patients With AECOPD Is Not A Good Indicator Of Acute Kidney Damage (AKI). <sup>[<xref ref-type="bibr" rid="ref-29">29</xref>]</sup> This Implies That Scr Is Not A Reliable Indicator Of Kidney Injury In Its Early Stages. This Restriction Is Justified Because Of Creatinine’s Half-Life, Which Can Range From 4 To 24 To 72 Hours When Gfr Declines, Limiting Its Usefulness As An Indicator Of The Renal Function. Furthermore, After A Major Renal Damage, It Could Take 24 To 36 Hours For Serum Creatinine Levels To Rise. <sup>[<xref ref-type="bibr" rid="ref-30">30</xref>]</sup> Moreover, Muscular Activity And The Quantities Produced In The Kidneys, Liver, And Pancreas All Affect Creatinine Production. <sup>[<xref ref-type="bibr" rid="ref-31">31</xref>]</sup></p>
      <p>When We Measured Cystatin C (Cys-C) And Β2-Microglobulin (Β2-Mg), We Found That Individuals With AECOPD Had Considerably Higher Average Serum Levels Of Both Biomarkers Than Patients With Stable COPD. This Observation Is Consistent With Zhang D.’S Study, Which Found Statistically Significant Variations In Cys-C And Β2-Mg Levels Throughout The AECOPD Cohort Compared To The Control Group. <sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup> Our Findings Also Support Those Of Chen D et al., Who Found Cystatin C To Be A Strong Independent Predictor Of Acute Kidney Injury (AKI) Among AECOPD Patients (Or 5.22; 95% Ci 2.49–10.95; P &lt; 0.001). <sup>[<xref ref-type="bibr" rid="ref-29">29</xref>]</sup> The Reason For This Phenomenon Is That Cases With AECOPD Frequently Have Lower Muscle And Fat Mass <sup>[<xref ref-type="bibr" rid="ref-32">32</xref>]</sup> , Which Results In A Real Drop-In Glomerular Filtration Rate (GFR), Which Is Accurately Represented By Cystatin C. Cystatin C Has A Half-Life That Is Almost 50% Shorter Than Creatinine, And Unlike Other Indicators, Its Levels Are Unaffected By Dietary Protein Intake, Age, Sex, Or Muscle Mass. <sup>[<xref ref-type="bibr" rid="ref-33">33</xref>]</sup> As A Result, Serum Levels Of Cystatin C Might Increase Before Creatinine <sup>[<xref ref-type="bibr" rid="ref-34">34</xref>]</sup> , Usually Within 24 To 48 Hours Of Even Minor Renal Damage. <sup>[<xref ref-type="bibr" rid="ref-35">35</xref>]</sup></p>
      <p>Those With Hypoxemia And AECOPD Had Significantly Higher Levels Of Acute Kidney Damage Markers, Notably Β2 Micro-Globulin And Cystatin C, Than Those With Normal Oxygen Levels. Additionally, It Was Discovered That The Degree Of Hypoxemia Was Correlated With Increased Average Amounts Of Cystatin C And Β2 Microglobulin. This Finding Is Consistent With Zhang D.’S Study, Which Showed That Levels Of Cystatin C And Β2 Micro-Globulin Increased Gradually As Hypoxia Increased, With Statistically Significant Differences Across The Different Groups In Numerous Comparisons <sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup> .</p>
      <p>According To The Results, Glomerular Hemodynamic Changes Brought On By Prolonged Hypoxia May Be Linked To The Renal Damage Shown In The Research Groups.<sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup> Because Hypoxemia Activates Vasoactive Substances Such As Endothelin And Angiotensin Ii, It Might Improve Renal Vascular Resistance, Which Can Reduce The Flow Of Renal Blood. <sup>[<xref ref-type="bibr" rid="ref-37">37</xref>]</sup> Hypoxia Can Also Cause Renal Tubular Epithelial Cells And Mesenchymal Cells To Differentiate Into Fibroblasts Or Trigger Apoptosis, Which Can Result In Tubulointerstitial Fibrosis And Either Cause Or Exacerbate Renal Damage. Those Processes Work Together To Cause Kidney Impairment In Those Who Are Impacted. Furthermore, The Release Of Inflammatory Mediators And Cytokines Might Be Markedly Increased During Acute Exacerbations. <sup>[<xref ref-type="bibr" rid="ref-38">38</xref>]</sup></p>
      <p>A Substantial Negative Correlation Was Found Between Β2 Microglobulin And The Partial Arterial Tension Of Oxygen (PaO2), But Β2 Microglobulin Levels And Both Cystatin C And PaCO2 Positively Correlated. Furthermore, Cystatin C Levels Showed A Strong Negative Association With PaO2 And A Positive Correlation With Β2 Micro-Globulin And PaCO2. These Results Are In Line With Zhang D.’S Study, Which Found That Cystatin C Levels Had A Negative Association With PaO2 And A Positive Correlation With hs-CRP, PaCO2, Serum Creatinine (Scr), And Blood Urea Nitrogen (BUN). Additionally, Β2 Microglobulin Levels Had A Negative Correlation With PaO2 And A Positive Correlation With hs-CRP, PaCO2, Scr, And BUN <sup>[<xref ref-type="bibr" rid="ref-7">7</xref>]</sup> .</p>
      <p>The Results Of The Multivariate Linear Regression Analysis On Β2 Micro-Globulin Levels Showed That Increased Cystatin C Levels, Growing Older, And The Existence And Degree Of Hypoxemia Were All Significant Predictors Of Higher Β2 Micro-Globulin Levels. In Particular, There Was A 0.015 Rise In Β2 Micro-Globulin Levels For Every Unit Drop In Oxygen Tension. Furthermore, Being Female, Having Β2 Micro-Globulin Levels, And Experiencing Exacerbations Were All Significant Predictors Of Cystatin C Levels.</p>
      <p>Our Study’s Limitations Were Mostly Brought On By Its Single-Center Design, Which Could Provide Results That Are Different From Those Found In Other Places, And Its Limited Sample Size, Which Might Result In Less Accurate Findings. Further Investigation Is Required To Examine How The Medication Being Delivered Affects The Levels Of Beta-2 Microglobulin And cystatin C, Particularly When Diuretics Are Used In Patients With Decompensated Cor Pulmonale.</p>
    </sec>
    <sec id="conclusion">
      <label>5</label>
      <title>Conclusion</title>
      <p>Elderly Individuals With Aecopd Frequently Experience Acute Kidney Injury, Which Is Positively Correlated With The Severity Of Hypoxemia And Hypercapnia. Cys-C And Β2-Mg Can Be Used As Sensitive Markers To Detect Renal Impairment Early In Older Adults With AECOPD. The Factors That Predicted An Increase In B2 Microglobulin Levels Were Age, The Degree Of Hypoxemia, And An Increase In Cystatin C Level. However, Higher B2 Microglobulin Levels, COPD Exacerbation, And Female Cases Were Predictors Of Elevated Cystatin C. Therefore, Addressing Risk Factors And Detecting Renal Impairment Early Can Improve The Outcome For Individuals With COPD.</p>
    </sec>
  </body>
  <back>
    <sec id="decl-funding" sec-type="funding-information">
      <title>Funding</title>
      <p>Non</p>
    </sec>
    <sec id="decl-contributions" sec-type="author-contributions">
      <title>Author contributions</title>
      <p>All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Morsi SN, Gadallah D, and Dongol EM. The first draft of the manuscript was written by Morsi SN and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <fn-group>
      <title>Competing interests</title>
      <fn id="decl-coi" fn-type="coi-statement">
        <p>The Researchers Declare That They Do Not Have Conflicts Of Interest.</p>
      </fn>
    </fn-group>
    <ack id="decl-acknowledgements">
      <title>Acknowledgements</title>
      <p>Not Applicable.</p>
    </ack>
    <sec id="decl-abbreviations" sec-type="abbreviations">
      <title>Abbreviations</title>
      <p><bold>COPD:</bold> Chronic Obstructive Pulmonary Disease; <bold>HF:</bold> Heart Failure; <bold>DM:</bold> Diabetes Mellitus; Ckd: Chronic Kidney Disease; <bold>AKI:</bold> Acute Kidney Injury; <bold>AECOPD:</bold> Acute Exacerbation Of Copd; <bold>Scr:</bold> Serum Creatinine; Cys-C: Cystatin C; <bold>GFR:</bold>Glomerular Filtration Rate; β<bold>2-Mg:</bold> Beta-2 (β2) Macroglobulin; <bold>CVD:</bold> Cerebrovascular Diseases And PaO2: Oxygen Partial Pressure.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="ref-1">
        <label>1</label>
        <mixed-citation>Barnes, Peter J et al. “Chronic obstructive pulmonary disease.” Nature reviews. Disease primers vol. 1 15076. 3 Dec. 2015, doi:<pub-id pub-id-type="doi">10.1038/nrdp.2015.76</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-2">
        <label>2</label>
        <mixed-citation>Global Initiative for Chronic Obstructive Lung Disease (2018). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org/wp-content/">http://www.goldcopd.org/wp-content/</ext-link> uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_ WMS.pdf. Accessed 17 Jan 2018.</mixed-citation>
      </ref>
      <ref id="ref-3">
        <label>3</label>
        <mixed-citation>Vogelmeier, Claus F et al. “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.” The European respiratory journal vol. 49,3 1700214. 6 Mar. 2017, doi:<pub-id pub-id-type="doi">10.1183/13993003.00214-2017</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-4">
        <label>4</label>
        <mixed-citation>World Health Organization (2024). Chronic Obstructive Pulmonary Disease (COPD). World Health Organization; Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/respiratory/copd/en/">http://www.who.int/respiratory/copd/en/</ext-link>. [Last accessed on 2024 NOV 6].</mixed-citation>
      </ref>
      <ref id="ref-5">
        <label>5</label>
        <mixed-citation>Corsonello, Andrea et al. “Comorbidities of chronic obstructive pulmonary disease.” Current opinion in pulmonary medicine vol. 17 Suppl 1 (2011): S21-8. doi:<pub-id pub-id-type="doi">10.1097/01.mcp.0000410744.75216.d0</pub-id></mixed-citation>
      </ref>
      <ref id="ref-6">
        <label>6</label>
        <mixed-citation>Incalzi, Raffaele Antonelli et al. “Chronic renal failure: a neglected comorbidity of COPD.” Chest vol. 137,4 (2010): 831-7. doi:<pub-id pub-id-type="doi">10.1378/chest.09-1710</pub-id></mixed-citation>
      </ref>
      <ref id="ref-7">
        <label>7</label>
        <mixed-citation>Zhang, Dong. “Correlation Analysis of Early Renal Injury in Elderly Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease.” International journal of chronic obstructive pulmonary disease vol. 17 2109-2115. 6 Sep. 2022, doi:<pub-id pub-id-type="doi">10.2147/COPD.S377847</pub-id></mixed-citation>
      </ref>
      <ref id="ref-8">
        <label>8</label>
        <mixed-citation>Celli, B R, and P J Barnes. “Exacerbations of chronic obstructive pulmonary disease.” The European respiratory journal vol. 29,6 (2007): 1224-38. doi:<pub-id pub-id-type="doi">10.1183/09031936.00109906</pub-id></mixed-citation>
      </ref>
      <ref id="ref-9">
        <label>9</label>
        <mixed-citation>Wedzicha, Jadwiga A, and Terence A R Seemungal. “COPD exacerbations: defining their cause and prevention.” Lancet (London, England) vol. 370,9589 (2007): 786-96. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(07)61382-8</pub-id></mixed-citation>
      </ref>
      <ref id="ref-10">
        <label>10</label>
        <mixed-citation>Zhang J, Chen F, Wang Y, et al. Early detection and prediction of acute exacerbation of chronic obstructive pulmonary disease. Chinese Medical Journal Pulmonary and Critical Care Medicine. 1. (2023):102-107.</mixed-citation>
      </ref>
      <ref id="ref-11">
        <label>11</label>
        <mixed-citation>Yi SB, Hu YF, Lin YH, Chen YX, Pan JY. Comparison on predictive value of blood lactic acid at different time periods for in-hospital mortality of septic patients: based on the medical information mart for intensive care III. Chin J Crit Care Med. 2020;13(1):39–43.</mixed-citation>
      </ref>
      <ref id="ref-12">
        <label>12</label>
        <mixed-citation>Abdelaal, Noha Ahmed et al. “Serum cystatin C as an earlier predictor of acute kidney injury than serum creatinine in preterm neonates with respiratory distress syndrome.” Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia vol. 28,5 (2017): 1003-1014. doi:<pub-id pub-id-type="doi">10.4103/1319-2442.215148</pub-id></mixed-citation>
      </ref>
      <ref id="ref-13">
        <label>13</label>
        <mixed-citation>Dharnidharka, Vikas R et al. “Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation vol. 40,2 (2002): 221-6. doi:<pub-id pub-id-type="doi">10.1053/ajkd.2002.34487</pub-id></mixed-citation>
      </ref>
      <ref id="ref-14">
        <label>14</label>
        <mixed-citation>Laterza, Omar F et al. “Cystatin C: an improved estimator of glomerular filtration rate?.” Clinical chemistry vol. 48,5 (2002): 699-707.</mixed-citation>
      </ref>
      <ref id="ref-15">
        <label>15</label>
        <mixed-citation>Elsayed, Mohamed Shawky et al. “Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus.” Diabetes &amp; metabolic syndrome vol. 13,1 (2019): 374-381. doi:<pub-id pub-id-type="doi">10.1016/j.dsx.2018.08.017</pub-id></mixed-citation>
      </ref>
      <ref id="ref-16">
        <label>16</label>
        <mixed-citation>Zaleska-Kociecka, Marta et al. “Serum beta-2 microglobulin levels for predicting acute kidney injury complicating aortic valve replacement.” Interactive cardiovascular and thoracic surgery vol. 25,4 (2017): 533-540. doi:<pub-id pub-id-type="doi">10.1093/icvts/ivx198</pub-id></mixed-citation>
      </ref>
      <ref id="ref-17">
        <label>17</label>
        <mixed-citation>Argyropoulos CP, Chen SS, Ng YH, Roumelioti ME, Shaffi K, Singh PP, Tzamaloukas AH. Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front Med (Lausanne). 2017 Jun 15;4:73. doi: <pub-id pub-id-type="doi">10.3389/fmed.2017.00073</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-18">
        <label>18</label>
        <mixed-citation>Global strategy for diagnosis, management, and prevention of COPD: 2024. Global Initiative for Chronic Obstructive Lung Disease. Available at <ext-link ext-link-type="uri" xlink:href="https://goldcopd.org/2024-gold-report/">https://goldcopd.org/2024-gold-report/</ext-link>. 2024; Accessed: October 9, 2024.</mixed-citation>
      </ref>
      <ref id="ref-19">
        <label>19</label>
        <mixed-citation>Ferguson, G. T., and B. Make. “Stable COPD: follow-up pharmacologic management.” 2022-09-16)[2022-11-08]. (2019).</mixed-citation>
      </ref>
      <ref id="ref-20">
        <label>20</label>
        <mixed-citation>Hosten AO. BUN and Creatinine. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 193.</mixed-citation>
      </ref>
      <ref id="ref-21">
        <label>21</label>
        <mixed-citation>Conde-Sánchez, Manuel et al. “Analytical performance evaluation of a particle-enhanced turbidimetric cystatin C assay on the Roche COBAS 6000 analyzer.” Clinical biochemistry vol. 43,10-11 (2010): 921-5. doi:<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2010.04.057</pub-id></mixed-citation>
      </ref>
      <ref id="ref-22">
        <label>22</label>
        <mixed-citation>Tian, S et al. “Cystatin C measurement and its practical use in patients with various renal diseases.” Clinical nephrology vol. 48,2 (1997): 104-8.</mixed-citation>
      </ref>
      <ref id="ref-23">
        <label>23</label>
        <mixed-citation>Barton, Kevin T et al. “Using the newer Kidney Disease: Improving Global Outcomes criteria, beta-2-microglobulin levels associate with severity of acute kidney injury.” Clinical kidney journal vol. 11,6 (2018): 797-802. doi:<pub-id pub-id-type="doi">10.1093/ckj/sfy056</pub-id></mixed-citation>
      </ref>
      <ref id="ref-24">
        <label>24</label>
        <mixed-citation>Mátrai, Zoltán et al. “Serum beta2-microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults.” Clinical chemistry and laboratory medicine vol. 47,5 (2009): 585-9. doi:<pub-id pub-id-type="doi">10.1515/CCLM.2009.137</pub-id></mixed-citation>
      </ref>
      <ref id="ref-25">
        <label>25</label>
        <mixed-citation>Wan, Xin et al. “Incidence, Risk Factors, and Prognostic Implications of Acute Kidney Injury in Patients with Acute Exacerbation of COPD.” International journal of chronic obstructive pulmonary disease vol. 15 1085-1092. 15 May. 2020, doi:<pub-id pub-id-type="doi">10.2147/COPD.S238343</pub-id></mixed-citation>
      </ref>
      <ref id="ref-26">
        <label>26</label>
        <mixed-citation>Fabbian, Fabio et al. “Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study.” International urology and nephrology vol. 48,7 (2016): 1121-7. doi:<pub-id pub-id-type="doi">10.1007/s11255-016-1272-5</pub-id></mixed-citation>
      </ref>
      <ref id="ref-27">
        <label>27</label>
        <mixed-citation>Barakat MF, McDonald HI, Collier TJ, Smeeth L, Nitsch D, Quint JK. Acute kidney injury in stable COPD and at exacerbation. Int J Chron Obstruct Pulmon Dis. 2015 Sep 28;10:2067-77. doi: <pub-id pub-id-type="doi">10.2147/COPD.S88759</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-28">
        <label>28</label>
        <mixed-citation>Chen H, Gao ZL. Clinical value of Cys C in early renal damage in patients with chronic kidney disease. J Trop Med. 2017;17(8):1047-1050.</mixed-citation>
      </ref>
      <ref id="ref-29">
        <label>29</label>
        <mixed-citation>Chen D, Cao C, Jiang L, Tan Y, Yuan H, Pan B, Ma M, Zhang H, Wan X. Serum cystatin C: A potential predictor for hospital-acquired acute kidney injury in patients with acute exacerbation of COPD. Chron Respir Dis. 2020 Jan-Dec;17:1479973120940677. doi: <pub-id pub-id-type="doi">10.1177/1479973120940677</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-30">
        <label>30</label>
        <mixed-citation>Ostermann, Marlies, and Michael Joannidis. “Acute kidney injury 2016: diagnosis and diagnostic workup.” Critical care (London, England) vol. 20,1 299. 27 Sep. 2016, doi:<pub-id pub-id-type="doi">10.1186/s13054-016-1478-z</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-31">
        <label>31</label>
        <mixed-citation>Thomas, Mark E et al. “The definition of acute kidney injury and its use in practice.” Kidney international vol. 87,1 (2015): 62-73. doi:<pub-id pub-id-type="doi">10.1038/ki.2014.328</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-32">
        <label>32</label>
        <mixed-citation>Schols, A M et al. “Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial.” American journal of respiratory and critical care medicine vol. 152,4 Pt 1 (1995): 1268-74. doi:<pub-id pub-id-type="doi">10.1164/ajrccm.152.4.7551381</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-33">
        <label>33</label>
        <mixed-citation>Kališnik, Jurij Matija et al. “Creatinine, Neutrophil Gelatinase-Associated Lipocalin, and Cystatin C in Determining Acute Kidney Injury After Heart Operations Using Cardiopulmonary Bypass.” Artificial organs vol. 41,5 (2017): 481-489. doi:<pub-id pub-id-type="doi">10.1111/aor.12779</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-34">
        <label>34</label>
        <mixed-citation>Gonzalez, F, and F Vincent. “Biomarkers for acute kidney injury in critically ill patients.” Minerva anestesiologica vol. 78,12 (2012): 1394-403.</mixed-citation>
      </ref>
      <ref id="ref-35">
        <label>35</label>
        <mixed-citation>Odutayo, Ayodele, and David Cherney. “Cystatin C and acute changes in glomerular filtration rate.” Clinical nephrology vol. 78,1 (2012): 64-75. doi:<pub-id pub-id-type="doi">10.5414/cn107324</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-36">
        <label>36</label>
        <mixed-citation>Hou J, Liu Y, Liu J, Chen X. Correlation between serum biochemical indices and renal pathology in elderly patients with nephropathy. Chin J Gerontol. 2014;34(20):5754–5756.</mixed-citation>
      </ref>
      <ref id="ref-37">
        <label>37</label>
        <mixed-citation>Huet, F et al. “Protective effect of perindoprilat in the hypoxemia-induced renal dysfunction in the newborn rabbit.” Pediatric research vol. 45,1 (1999): 138-42. doi:<pub-id pub-id-type="doi">10.1203/00006450-199901000-00023</pub-id>.</mixed-citation>
      </ref>
      <ref id="ref-38">
        <label>38</label>
        <mixed-citation>Ghosh, N., Choudhury, P., Kaushik, S.R. et al. Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO). Respir Res 21, 126 (2020). https://doi.org/<pub-id pub-id-type="doi">10.1186/s12931-020-01390-4</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
